Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%

Deep News

01/23

On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.

Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.

On individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1142659698"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142659698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142659698?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 10:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142659698","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%","media":"Deep News","content":"<p>On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.</p>\n<p>Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.</p>\n<p>On individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2026-01-23 10:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.</p>\n<p>Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.</p>\n<p>On individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2778985437.USD","symbol_name":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1142659698","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142659698","pubTimestamp":1769135501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory. Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","BK1574":"生物医药B类股","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","02800":"盈富基金","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","06978":"永泰生物-B","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","09926":"康方生物","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","BK1610":"ETF&股票定投概念","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC"},"translate_title":"港股创新药概念延续涨势康方生物大涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"02800":1,"09926":1},"content_text":"On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.\nEverest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.\nOn individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}